ABIOMED Inc

ABIOMED — Q3 2022 Earnings Presentation

11 slides from ABIOMED's earnings presentation, Feb 3, 2022

  1. Slide 1: Q3 FY 2022 Earnings Call

    ® Recovering Hearts. Saving Lives. Q3 FY 2022 Earnings Call Financial Results & Operational Highlights Recovering Hearts. Saving Lives.

  2. Slide 2: Financial Results, Q3 FY 2022

    2 FINANCIAL RESULTS, Q3 FY 2022 Fiscal Year ends March 31 Revenue ($M) & Growth Rates Cash* ($M) $261 $932 $253 $248 $848 $862 $241 $788 $805 $232 YOY +5% +17% +53% +18% +13% Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 *Abiomed has no debt 1 Gross Margin % Operating Margin % 82.3% 82

  3. Slide 3: U.S. Utilization Mix, Q3 FY 2022

    3 U.S. UTILIZATION MIX, Q3 FY 2022 Revenue by Impella® Device Utilization by Indication Impella 5.0® / 5.5 (18%) Other Impella RP® (4%) (4%) Emergent (55%) Impella 2.5® (3%) ® Impella CP ® Protected PCI (75%) (41%) U.S. Hospital Site Penetration Patient Performance Revenue Performance3 Impella® Devi

  4. Slide 4: FY 2022 Guidance Post Q3; Increased Lower End

    4 FY 2022 GUIDANCE POST Q3; INCREASED LOWER END Abiomed FY’22 Abiomed FY’22 Abiomed FY’22 Abiomed FY’22 Original Guidance Post-Q1 Guidance Post-Q2 Guidance Post-Q3 Guidance Revenue Revenue Revenue Revenue $990M - $1.03B $1.03B - $1.05B $1.01B - $1.03B $1.025B - $1.03B +17 - 22% YOY +22 - 24% YOY +19

  5. Slide 5: Abiomed Clinical Trials and Innovation Milestones

    5 ABIOMED CLINICAL TRIALS AND INNOVATION MILESTONES Patient Study Detail Total Sites Status Enrollment New Indication for heart attacks without CGS. STEMI DTU Pivotal follows successful FDA Pilot study on 119 out of 788* 39 out of 60 TBD with COVID resolution FDA RCT Study reperfusion and ventricula

  6. Slide 6: Abiomed 2.0 Platform: Impella, ECMO, preCARDIA

    6 ABIOMED 2.0 PLATFORM: IMPELLA, ECMO, PRECARDIA PERCUTANEOUS INSERTION PRECARDIATM FDA EFS* Impella 2.5® Impella CP® with SmartAssist® 24/7 Support Onsite, On-Call, Online with AI Capability Impella ECPTM FDA EFS* RIGHT HEART ECMO Impella RP® Impella RP IJTM >500 Global Field Reps Clinical Support

  7. Slide 7: Abiomed 2.0 Premier Field Team: 24x7 On-Site, On-Call and Online

    7 ABIOMED 2.0 PREMIER FIELD TEAM: 24X7 ON-SITE, ON-CALL AND ONLINE WITH AI Physician Nurse Patient in Station ICU Online Patient ON-SITE ON-CALL Metrics & AI ONLINE Abiomed Abiomed Clinical AIC with SmartAssist® Clinical Team Support Center & Impella Connect FOR INVESTORS ONLY

  8. Slide 8: Protocolized Shock Teams Use More Impella, Less IABP and Improve Outcomes

    8 PROTOCOLIZED SHOCK TEAMS USE MORE IMPELLA, LESS IABP AND IMPROVE OUTCOMES More Impella Less IABP Conclusion: In this multicenter observational study, centers with shock teams were more likely to obtain invasive hemodynamics, use advanced types of MCS, and have lower risk-adjusted mortality. A stan

  9. Slide 9: Appendix

    9 APPENDIX FOR INVESTORS ONLY Recovering Hearts. Saving Lives.

  10. Slide 10: Abiomed's Innovation and Sustainable Growth

    10 ABIOMED’S INNOVATION AND SUSTAINABLE GROWTH TODAY FUTURE* TM IMPELLA IMPELLA CP® IMPELLA RP® IMPELLA 5.5® SMARTASSIST® IMPELLA IMPELLA XR BREETHE OXY-1 IMPELLA IMPELLA PRECARDIA 2.5® with SmartAssist® with SmartAssist® with SmartAssist® with AI Algorithms CONNECT® SHEATHTM SYSTEMTM ECPTM BTRTM PR

  11. Slide 11: Heart, Lung and Kidney Failure: A Growing Crisis

    11 HEART, LUNG AND KIDNEY FAILURE: A GROWING CRISIS #1 CAUSE OF DEATH IN U.S. IS CAD HF >15M people have CAD driving 875,000 deaths per year Obesity & Type II diabetes increasing heart attacks and kidney failure 1 CAD is the #1 cause of death for Type II Diabetes1 #1 CAUSE OF HOSPITALIZATIONS AND LE

ABIOMED — Q3 2022 Earnings Presentation on 6ix